Official UK procurement notice
REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES
Authority: Business Energy and Industrial Strategy
What is being bought
Published requirement descriptionProcurement for REGN-COV2.
CPV: Pharmaceutical products
The lotProcurement structure
single lot · no lot value publishedLot #1Procurement for REGN-COV2Awarded
Procurement for REGN-COV2. Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors .
Procedure terms & legal framework
From the official record- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 1 Apr 2021, 18:14 BST
- Last source update
- 1 Apr 2021, 18:14 BST
- Authority reference
4964/03/2021- FTS notice number
2021/S 000-006891- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-02a25cFind a Tender
- Why no open competition
Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive
- Published justification
Our position, after reviewing the advice from counsel, is that under the unforeseen current global public health crisis there is a strong argument that the direct award of a contract with Roche is compliant with current PCR regulations in respect to section 32(2)(c). Firstly, the urgent award to Roche is strictly necessary to prevent significant loss of life, disease, and protracted periods of continued economic stress. Delay in acquiring binding assurances to reserves of antibody doses would pose an imminent risk for long term procurement of a antibody to combat the Covid-19 pandemic. Therefore, the UKs adoption of a protectionist approach to acquiring the Regeneron antibody via a direct award is fully justified under PCR regulation 32(2)(c).
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Roche Products Ltd | £1 † | — | Awarded |
Contracts
REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES · Roche Products Ltd
- Signed
- 5 Mar 2021
- Value
- £1
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids | — | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Department of Business, Energy and Industrial StrategyReview body
Bidders & participating suppliers
1 commercial party on the notice- Roche Products LimitedAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.